Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus.
about
Crosstalk between innate and adaptive immunity in hepatitis B virus infectionRestoring homeostasis of CD4⁺ T cells in hepatitis-B-virus-related liver fibrosisDecreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatmentChanges of costimulatory molecule CD28 on circulating CD8+ T cells correlate with disease pathogenesis of chronic hepatitis BHyper-activated pro-inflammatory CD16 monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B.Natural killer cells are characterized by the concomitantly increased interferon-γ and cytotoxicity in acute resolved hepatitis B patients.Unique hepatitis B virus subgenotype in a primitive tribal community in eastern India.Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China.Gut microbiota modulate the immune effect against hepatitis B virus infection.Regulation of T cell function by microRNA-720.Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patientsCynomolgus monkeys (Macaca fascicularis) experimentally infected with B19V and hepatitis A virus: no evidence of the co-infection as a cause of acute liver failure.Peripheral type I interferon receptor correlated with oxidative stress in chronic hepatitis B virus infection.Design of therapeutic vaccines: hepatitis B as an example.Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapyImmunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection.The role of innate immunity in HBV infection.Non-antigen-specific and antigen-specific immune therapies for chronic hepatitis B: evidences from laboratory benches and patient's bedsides.Treating Immune-tolerant Hepatitis B.Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.Molecular mechanisms of HBeAg in persistent HBV infection.Baseline CD4+ T-cell counts predict HBV viral kinetics to adefovir treatment in lamivudine-resistant HBV-infected patients with or without HIV infection.Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss.Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B.Enhanced high-mobility group box 1 (HMGB1) modulates regulatory T cells (Treg)/T helper 17 (Th17) balance via toll-like receptor (TLR)-4-interleukin (IL)-6 pathway in patients with chronic hepatitis B.Interleukin-21 mediates hepatitis B virus-associated liver cirrhosis by activating hepatic stellate cells.Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner.
P2860
Q26771142-5C83364A-6B70-4303-9CC1-C40C85174B91Q26782048-A2DC5E88-0B31-4716-8725-2DC83297B09AQ33747793-9DF4DD2A-3E21-4775-9B0A-AB9F1CFEA3A0Q33809735-2382F6A3-AB0D-40A3-9EBF-D92604223D05Q33842114-0B755C6E-C8BD-4E1A-B788-1E4C69C1D8BAQ34469926-4E567BB9-FBDA-4485-9704-43C12A514206Q34489372-A0CCDEAD-29DC-45E0-93FD-EC18BEE81B4DQ35173805-4ABA98B6-D3AF-4423-8745-4590C520A290Q35745517-86845E76-DCC2-404B-927C-26722BFFD710Q35877272-809748AB-3C8F-44DB-8434-17915A0E5894Q36302694-AC9E9CEF-E7F0-4884-8167-3970BA384E94Q36793876-8D67216B-9609-4AA7-86B2-9B7F9384E3A5Q37089964-B33D0650-7311-4ED8-9808-34937BCA672FQ37274697-5F03BE72-942A-448E-986E-51CAFFA40D96Q37632321-E9A79005-C984-4719-B1E6-DE8E6BC8A3E9Q37946440-8205B474-3F96-4C3C-A68C-738D37269445Q38027754-846B3940-73CE-4436-8531-D1D809A750E0Q38098583-123DEAA1-6D6B-4528-AF8E-7A08DB8C8DDFQ38271430-280B580B-5C7E-42A5-A5C4-4F3076C9DC5AQ38738345-6465BF74-E622-45BF-8B05-3C9B905AF5FFQ40669256-903DE23C-E9AB-45C9-8D80-0A880EAA3800Q41539359-73BF19CE-7564-48A1-8DA3-79251D9D767BQ42215188-B851F2F1-F6A4-4840-8F30-0C1E320CC90CQ42219588-747A8362-69A7-4A29-AA1E-E944E4279A97Q42245702-B59B4F14-493C-4A50-9830-4275F5DB85A0Q42279852-83D0EC2F-74C5-49F9-BD23-C1DAAB3BFA6BQ45365303-1FF3E51A-EF23-4F30-A6FA-2C90FA00EE58
P2860
Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Host immunity influences disea ...... fected with hepatitis B virus.
@en
Host immunity influences disea ...... fected with hepatitis B virus.
@nl
type
label
Host immunity influences disea ...... fected with hepatitis B virus.
@en
Host immunity influences disea ...... fected with hepatitis B virus.
@nl
prefLabel
Host immunity influences disea ...... fected with hepatitis B virus.
@en
Host immunity influences disea ...... fected with hepatitis B virus.
@nl
P2860
P356
P1476
Host immunity influences disea ...... fected with hepatitis B virus.
@en
P2093
Fu-Sheng Wang
Zheng Zhang
P2860
P304
P356
10.1586/EGH.09.50
P577
2009-10-01T00:00:00Z